Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. (Nasdaq: SMLR) is an innovative medical risk-assessment company focused on developing, manufacturing, and marketing diagnostic and testing products that enhance patient care while bridging the gap between the cost of care and its compensation. Listed on Nasdaq since February 26, 2014, Semler operates primarily in the United States, offering proprietary technology solutions that improve clinical effectiveness and efficiency for healthcare providers, insurance plans, and risk assessment groups.
Semler's flagship product, QuantaFlo®, is a rapid, in-office test for measuring arterial blood flow in the extremities. This four-minute test aids in diagnosing peripheral arterial disease (PAD) and heart dysfunction (HD). QuantaFlo® is FDA-cleared and is employed by healthcare providers to evaluate patients' risks of mortality and major adverse cardiovascular events (MACE).
Beyond QuantaFlo®, Semler Scientific has made strategic alliances and investments to expand its product portfolio. The company has an exclusive marketing and distribution agreement with Mellitus Health, Inc. for Insulin Insights™, an FDA-cleared software product that recommends optimal insulin dosing for diabetic patients. Additionally, Semler holds minority investments in Mellitus, Monarch Medical Technologies LLC (developer of EndoTool® for inpatient glycemic management), and SYNAPS Dx.
In the latest financial results for Q3 2023, Semler reported consistent growth in quarterly revenue and pre-tax net income, predominantly from QuantaFlo® sales. The company continues to focus on expanding its business into heart dysfunction diagnosis.
Semler has also recently adopted Bitcoin as its primary treasury reserve asset, reflecting a strategic move to leverage the digital currency for long-term value and as a hedge against inflation. As of June 6, 2024, the company holds 828 bitcoins, underscoring its commitment to this innovative investment strategy.
More detailed information about Semler Scientific, its products, and investment strategies can be found on their website.
Semler Scientific (NASDAQ: SMLR) reported Q3 2024 financial results showing revenues of $13.5M, down 17% year-over-year, and net income of $5.6M ($0.80 per basic share). The company announced additional bitcoin purchases, bringing total holdings to 1,058 bitcoins acquired for $71.0M. Income from operations was $5.1M, a 20% decrease from Q3 2023. The company's two largest customers comprised 44% and 29% of Q3 2024 revenues. Semler continues to focus on bitcoin acquisition while maintaining its healthcare business, utilizing both operating cash flow and ATM program proceeds for purchases.
Semler Scientific (Nasdaq: SMLR) has announced it will report financial results for the third quarter and nine months ended September 30, 2024, and provide an update on its Bitcoin holdings after the close of U.S. financial markets on Monday, November 4, 2024. The company will host a conference call at 4:30 pm ET the same day, led by CEO Doug Murphy-Chutorian, along with Chairman Eric Semler, CFO Renae Cormier, and COO Jennifer Oliva-Herrington.
Participants are encouraged to pre-register for the call using the provided link. Those unable to pre-register can dial in using the domestic (833-816-1161) or international (412-317-0617) numbers. Questions can be submitted prior to the call via email to ir@semlerscientific.com. The conference call will be archived on Semler Scientific's website.
Semler Scientific (Nasdaq: SMLR) has announced the purchase of an additional 83 bitcoins for $5.0 million in cash, including fees and expenses. As of August 26, 2024, the company now holds a total of 1,012 bitcoins, acquired for a cumulative $68.0 million. Eric Semler, chairman of Semler Scientific, stated that the purchase was made using primarily cash from operations and capital raised through their at-the-market equity program.
The company expressed optimism about the growing institutional adoption of bitcoin, noting that institutions now own more than 20% of bitcoin ETF assets under management. Semler believes this increasing institutionalization will drive value for both bitcoin prices and their stockholders.
Semler Scientific (NASDAQ: SMLR) reported Q2 2024 financial results and additional Bitcoin purchases. Key points:
- Revenues decreased 22% to $14.5 million
- Income from operations fell 25% to $5.4 million
- Net income dropped to $11,000 from $5.9 million in Q2 2023
- Purchased 929 bitcoins for $63 million total
- Bitcoin holdings fair value of $54.9 million as of June 30, reflecting $5.1 million reduction
The company remains focused on acquiring Bitcoin while supporting its healthcare business. Semler plans to purchase more Bitcoin using cash from operations and potentially from selling securities under a $150 million shelf registration statement.
Semler Scientific (Nasdaq: SMLR), a company focused on developing technology solutions for chronic disease management in healthcare, has announced its plans to report financial results for Q2 and H1 2024 on August 5, 2024, after U.S. market close. The company will host a conference call at 4:30 pm ET on the same day, led by CEO Doug Murphy-Chutorian, with participation from Chairman Eric Semler, CFO Renae Cormier, and COO Jennifer Oliva-Herrington.
Investors are encouraged to submit questions in advance to ir@semlerscientific.com and pre-register for the call. Those unable to pre-register can dial in using provided domestic and international numbers. The call will be archived on Semler Scientific's website for future reference.
Semler Scientific announced the purchase of an additional 247 bitcoins for $17 million in cash, including fees and expenses. This brings their total bitcoin holdings to 828, acquired for $57 million. CEO Doug Murphy-Chutorian emphasized their dual strategy of expanding their healthcare business and investing in bitcoin, viewing it as a reliable store of value. As of June 6, 2024, the company continues to focus on these strategies.
Semler Scientific (Nasdaq: SMLR) has adopted bitcoin as its primary treasury reserve asset, purchasing 581 bitcoins for $40 million. Chairman Eric Semler stated that bitcoin's scarcity and digital resilience make it a superior store of value and a potential hedge against inflation compared to gold. The SEC's approval of bitcoin exchange-traded funds and institutional investments validate this strategy. Despite the bitcoin focus, Semler will continue prioritizing its core medical products, particularly QuantaFlo® for peripheral arterial disease testing, while seeking FDA clearance for expanded labeling. Bitcoin holdings will be subject to market conditions and cash needs.
Semler Scientific, Inc. reported $15.9 million in revenue for the first quarter of 2024, a 13% decrease from the same period in 2023. Net income increased by 22% to $6.1 million. The company's cash balance rose to $62.9 million. Despite revenue decline from the PAD product, the CEO remains optimistic about future revenue growth pending FDA clearance for a new product. Semler Scientific also achieved year-over-year net income growth and a record cash balance.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
What does Semler Scientific, Inc. do?
What is QuantaFlo®?
When did Semler Scientific go public?
What recent achievements has Semler Scientific made?
What is Insulin Insights™?
How is Semler Scientific involved with Bitcoin?
Who are Semler Scientific’s primary customers?
Where is Semler Scientific headquartered?
What other companies is Semler Scientific invested in?
What is the financial outlook for Semler Scientific?
